Welcome to Markets Desk, here's what's moving the needle this hour.
Merck and Moderna are pushing shares higher on fresh momentum behind their personalized cancer vaccine, designed to target each patient's individual tumor profile. The approach addresses melanoma recurrence, one of oncology's most stubborn problems, and Wall Street is reading the science as a genuine pipeline catalyst for both names.
Shifting to the broader market, the AI-powered rally that drove equities through two thousand twenty six is now facing a credibility test heading into two thousand twenty seven. Earnings growth has been the engine, but analysts are flagging signs that the blockbuster profit expansion underpinning tech valuations may be approaching its ceiling, which would force a serious repricing conversation.
And in the digital assets space, Standard Chartered is making a bold call, projecting the stablecoin market reaches two trillion dollars by two thousand thirty. That's not fringe analysis, that's one of the world's largest trade finance banks putting a number on institutional adoption, and it carries weight as regulatory frameworks begin taking shape in Washington and Brussels.
That's the tape. Markets Desk, signing off the floor.
